At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...
Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...
Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, ...
Researchers from MD Anderson identified DHODH as a key metabolic driver of radiotherapy resistance in lung cancer. Radiation ...
BioNTech and DualityBio reported encouraging Phase 2 results for trastuzumab pamirtecan, an investigational HER2-targeted ...
A new study led by UCL researchers suggests that making cancer cells more visible to the immune system could broaden the ...
FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...
Researchers at MD Anderson identified DPY30 as a key biomarker and epigenetic regulator that enables pancreatic tumors to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results